Skip to main content

Table 3 Standardized dataset for the cost-effectiveness models in rotavirus vaccination: vaccine characteristics (Sources: [15, 7, 15, 20, 28], expert opinions)

From: Comparative review of three cost-effectiveness models for rotavirus vaccines in national immunization programs; a generic approach applied to various regions in the world

  Afr Sear Amr Eur Notes
Efficacy, assuming a 2-dose schedule at 2 & 3 months (1 dose only between brackets)      
   Mild 52% (52%) 52% (52%) 52% (52%) 87% (87%)  
   Moderate 55% (54%) 55% (54%) 55% (54%) 92% (90%)  
   Severe 60% (54%) 60% (54%) 60% (54%) 100% (90%)  
Waning of efficacy (annual)      
   Mild & moderate 0.63 0.63 0.63 0.63 multiply each next year
   Severe 0.83 0.83 0.83 0.83 multiply each next year
Coverage      
   Dose 1 50% 50% 50% 50%  
   Dose 2 40% 40% 40% 40%  
   20 years after introduction 80% 80% 80% 96% for both doses
   Coverage improvement linear linear linear linear  
Per-dose vaccine costs (2 doses)     
   2009-2014 7.5 7.5 7.5 45  
   2015 & beyond 4 4 4 45